Targeted attack on hidden leukemia cells after chemo
NCT ID NCT05456698
Summary
This study is testing a targeted drug called inotuzumab ozogamicin for adults with a type of acute lymphoblastic leukemia (ALL). It is for patients who have responded to initial chemotherapy but still have very low levels of detectable cancer cells, known as minimal residual disease (MRD). The main goal is to see if this drug can eliminate these remaining cells and prevent the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.